IM Cannabis Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oren Shuster
- Full Time Employees
- 95
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Kibbutz Glil Yam Tel Aviv Israel 4690500
- IPO Date
- May 20, 2020
- CIK
- 0001792030
- Website
- imcannabis.com
- Similar Companies
- Business
- IM Cannabis Corp. is an international medical cannabis company founded in 2008 and headquartered in Canada, operating primarily in Israel and Germany, two of the largest medical cannabis markets. The company produces a range of premium medical cannabis products including dried cannabis flowers, extracts, and other pharmaceutical cannabis formulations, which it sells through its vertically integrated supply chain encompassing breeding, cultivation, importation, distribution, retail pharmacies, online platforms, distribution centers, and logistical hubs. IM Cannabis operates through Israeli subsidiaries such as Focus Medical Herbs Ltd. and owns Adjupharm GmbH in Germany, which distributes medical cannabis to pharmacies. IM Cannabis recently exited its Canadian operations to prioritize sustainable growth in its highest value markets of Israel and Germany. In 2025, it expanded its product portfolio by launching new cannabis brands including the mid-market "Token" and value brand "Mids," alongside established brands such as "Selected" and the ultra-premium Canadian BLKMKT. The company signed a multi-year supply agreement with Canadian LP The Flowr Corporation to import ultra-premium cannabis, enhancing its product offerings. IM Cannabis also announced the acquisition of a 60% stake in an innovative quantum computing bio data company for up to $54 million, marking a strategic diversification into advanced biological data processing technologies. Additionally, IM Cannabis is expanding its retail footprint via acquisitions like Oranim Pharm, one of Jerusalem's leading medical cannabis pharmacies. The company leverages a data-driven ecosystem powered by proprietary patient insights and advanced supply chain management, emphasizing compliance with strict regulatory environments to maintain high product quality and safety standards. IM Cannabis achieved a positive turnaround in early 2025 with improved profitability metrics, including a net profit and significantly enhanced gross margins, reflecting operational efficiencies and a strong market position in the medical cannabis sector. The company's ongoing investments in technology, product innovation, and strategic partnerships aim to strengthen its global brand and commercial presence in the competitive pharmaceutical and biotech industry.
IM Cannabis Corp. Announces First Quarter 2026 Financial Results
IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
Stryker (NYSE:SYK) & IM Cannabis (NASDAQ:IMCC) Critical Analysis
IM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash Flow
Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)
IMC Announces a Strategic Entry to the Cyber Drone Interception and Satellite Intelligence Markets by Signing a Non-Binding Agreement to Acquire 51% of Blackaxe Technologies
IM Cannabis (NASDAQ:IMCC) Stock Price Down 5% – Should You Sell?
IM Cannabis (NASDAQ:IMCC) Stock Price Down 5% – What’s Next?
IM Cannabis Raises US$2,171,660.40 in Note Purchase Agreements
IM Cannabis Announces the Appointment of Mr. Alon Dayan to its Board of Directors
IM Cannabis Explores U.S. Market Entry Following President Trump's Executive Order on Increasing Medical Marijuana and Cannabidiol Research
Head-To-Head Review: IM Cannabis (NASDAQ:IMCC) versus DiaSorin (OTCMKTS:DSRLF)
IM Cannabis Appoints Asi Levi as Chief Financial Officer
IM Cannabis Reports Third Quarter 2025 Financial Results
IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ET
IM Cannabis Announces CFO Departure
Cannabis Investing 2025: 3 Pot Stocks to Watch Before November
IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 Million
IM Cannabis Announces Board Changes and Strategic Decision to Identify Additional Business Opportunities